Dynorphin A as a potential endogenous ligand for four members of the opioid receptor gene family. 1998

S Zhang, and Y Tong, and M Tian, and R N Dehaven, and L Cortesburgos, and E Mansson, and F Simonin, and B Kieffer, and L Yu
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, USA.

Dynorphin A is an endogenous opioid peptide that activates the kappa opioid receptor (KOR) with high potency. Some studies also showed that the distribution and functional activity of dynorphin A are not completely correlated with those of KOR, suggesting that dynorphin A may interact with other receptors. To investigate the possibility that dynorphin A may serve as an agonist for other opioid receptors, we took the advantage of the cloning of the three major types of opioid receptors, mu (MOR), delta (DOR) and KOR, and examined their affinity for and their activation by dynorphin A. We used mammalian cells transfected with each of the cDNA clones for the human receptors hMOR, hDOR, hKOR and showed that dynorphin A displaced [3H]-diprenorphine binding with Ki values in the nanomolar range at all three receptors. We also showed that, when hMOR, hDOR or hKOR was coexpressed with a G protein-activated potassium channel in Xenopus oocytes, dynorphin A induced a potassium current with EC50 values in the nanomolar range for all three receptors. Furthermore, we showed that the human hORLI, an opioid receptor-like receptor that has been identified as a novel member of the opioid receptor gene family, displayed dynorphin A binding and functional activation. These results indicate that dynorphin A is capable of binding to and functional activation of all members of the opioid receptor family, suggesting that, as a potential endogenous agonist, its activity in humans may involve interaction with other members of the opioid receptor family in addition to kappa receptors.

UI MeSH Term Description Entries
D011957 Receptors, Opioid Cell membrane proteins that bind opioids and trigger intracellular changes which influence the behavior of cells. The endogenous ligands for opioid receptors in mammals include three families of peptides, the enkephalins, endorphins, and dynorphins. The receptor classes include mu, delta, and kappa receptors. Sigma receptors bind several psychoactive substances, including certain opioids, but their endogenous ligands are not known. Endorphin Receptors,Enkephalin Receptors,Narcotic Receptors,Opioid Receptors,Receptors, Endorphin,Receptors, Enkephalin,Receptors, Narcotic,Receptors, Opiate,Endorphin Receptor,Enkephalin Receptor,Normorphine Receptors,Opiate Receptor,Opiate Receptors,Opioid Receptor,Receptors, Normorphine,Receptors, beta-Endorphin,beta-Endorphin Receptor,Receptor, Endorphin,Receptor, Enkephalin,Receptor, Opiate,Receptor, Opioid,Receptor, beta-Endorphin,Receptors, beta Endorphin,beta Endorphin Receptor,beta-Endorphin Receptors
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004399 Dynorphins A class of opioid peptides including dynorphin A, dynorphin B, and smaller fragments of these peptides. Dynorphins prefer kappa-opioid receptors (RECEPTORS, OPIOID, KAPPA) and have been shown to play a role as central nervous system transmitters. Dynorphin,Dynorphin (1-17),Dynorphin A,Dynorphin A (1-17)
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014981 Xenopus An aquatic genus of the family, Pipidae, occurring in Africa and distinguished by having black horny claws on three inner hind toes.
D017450 Receptors, Opioid, mu A class of opioid receptors recognized by its pharmacological profile. Mu opioid receptors bind, in decreasing order of affinity, endorphins, dynorphins, met-enkephalin, and leu-enkephalin. They have also been shown to be molecular receptors for morphine. Morphine Receptors,Opioid Receptors, mu,Receptors, Morphine,Receptors, mu,Receptors, mu Opioid,mu Receptors,Morphine Receptor,mu Opioid Receptor,mu Receptor,Opioid Receptor, mu,Receptor, Morphine,Receptor, mu,Receptor, mu Opioid,mu Opioid Receptors
D017465 Receptors, Opioid, delta A class of opioid receptors recognized by its pharmacological profile. Delta opioid receptors bind endorphins and enkephalins with approximately equal affinity and have less affinity for dynorphins. Opioid Receptors, delta,Receptors, delta,Receptors, delta Opioid,delta Receptors,delta Opioid Receptor,delta Receptor,Opioid Receptor, delta,Receptor, delta,Receptor, delta Opioid,delta Opioid Receptors
D017473 Receptors, Opioid, kappa A class of opioid receptors recognized by its pharmacological profile. Kappa opioid receptors bind dynorphins with a higher affinity than endorphins which are themselves preferred to enkephalins. Opioid Receptors, kappa,Receptors, kappa,Receptors, kappa Opioid,kappa Receptors,kappa Opioid Receptor,kappa Receptor,Opioid Receptor, kappa,Receptor, kappa,Receptor, kappa Opioid,kappa Opioid Receptors

Related Publications

S Zhang, and Y Tong, and M Tian, and R N Dehaven, and L Cortesburgos, and E Mansson, and F Simonin, and B Kieffer, and L Yu
April 2006, Journal of neurochemistry,
S Zhang, and Y Tong, and M Tian, and R N Dehaven, and L Cortesburgos, and E Mansson, and F Simonin, and B Kieffer, and L Yu
January 1982, Science (New York, N.Y.),
S Zhang, and Y Tong, and M Tian, and R N Dehaven, and L Cortesburgos, and E Mansson, and F Simonin, and B Kieffer, and L Yu
January 1984, The Journal of pharmacology and experimental therapeutics,
S Zhang, and Y Tong, and M Tian, and R N Dehaven, and L Cortesburgos, and E Mansson, and F Simonin, and B Kieffer, and L Yu
December 1988, Pharmaceutical research,
S Zhang, and Y Tong, and M Tian, and R N Dehaven, and L Cortesburgos, and E Mansson, and F Simonin, and B Kieffer, and L Yu
July 1996, Sheng li ke xue jin zhan [Progress in physiology],
S Zhang, and Y Tong, and M Tian, and R N Dehaven, and L Cortesburgos, and E Mansson, and F Simonin, and B Kieffer, and L Yu
November 2012, British journal of pharmacology,
S Zhang, and Y Tong, and M Tian, and R N Dehaven, and L Cortesburgos, and E Mansson, and F Simonin, and B Kieffer, and L Yu
September 2001, Japanese journal of pharmacology,
S Zhang, and Y Tong, and M Tian, and R N Dehaven, and L Cortesburgos, and E Mansson, and F Simonin, and B Kieffer, and L Yu
January 1996, Proceedings of the Western Pharmacology Society,
S Zhang, and Y Tong, and M Tian, and R N Dehaven, and L Cortesburgos, and E Mansson, and F Simonin, and B Kieffer, and L Yu
December 2012, Neuropeptides,
S Zhang, and Y Tong, and M Tian, and R N Dehaven, and L Cortesburgos, and E Mansson, and F Simonin, and B Kieffer, and L Yu
January 1996, Journal of leukocyte biology,
Copied contents to your clipboard!